To elucidate further the potential of a Semliki Forest virus IL-12 genes induced tumor regression, the antiangiogenic-(SFV) vector in vivo for gene therapy, we constructed a activity of SFV-IL12 was investigated using Doppler ultravector, SFV-IL12, to transfer murine IL-12 genes into sonography (DUS). SFV-IL12 inhibited in situ neovascutumors. A single intratumoral injection of established B16 larization within the tumor, without affecting the resistance murine melanoma with SFV-IL12 resulted in a significant index of pre-existing intratumoral blood flows. In addition, inhibition of tumor growth, while injection with SFV-LacZ histological analysis of SFV-IL12-treated tumors showed had no effect. This antitumoral activity correlated with an massive tumor necrosis induced by SFV-IL12 treatment. increase of IFN␥ production, MIG and IP-10 mRNA These data indicate that SFV-IL12 inhibits tumor growth expression, both at the tumor site and at the periphery. In through its antiangiogenic activity, demonstrated for the contrast, no increase in CTL-or NK cell-mediated cytotoxic first time in vivo by DUS, and suggest that the SFV vector response could be detected, ruling out the involvement of may be a novel valuable tool in tumor gene transfer. T and NK cell cytotoxicity. To determine how the transfer of